News

Location:homepage  News

Congratulations on the publication of Jie Ding's paper by Analytical Chemistry!

发表时间:2015-12-01 阅读次数:462

 

Screening of HER2 Overexpressed Breast Cancer Subtype In Vivo by the Validation of High-Performance, Long-Term, and Noninvasive Fluorescence Tracer

 State Key Laboratory of Analytical Chemistry for Life Science, Collaborative Innovation of Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210093, China
 China-America Cancer Research Institute, Guangdong Medical University, Dongguan, Guangdong 523808, China
§ School of Medical Imaging, Xuzhou Medical College, Xuzhou 221004, China
Anal. Chem.201587 (24), pp 12290–12297
DOI: 10.1021/acs.analchem.5b03580
Publication Date (Web): November 24, 2015
Copyright © 2015 American Chemical Society
*E-mail: jjzhu@nju.edu.cn., *E-mail: zhiweihe688@163.com., *E-mail: jianglp@nju.edu.cn.

Abstract

Abstract Image

The high-performance and noninvasive screening of heterogeneous tumor subtypes in vivo is particularly desirable for the diagnosis and symptomatic treatment of cancer. Therefore, we report a near-infrared (NIR) fluorescence tracer “smartly identified HER2” (SI-HER2) for rapid, accurate, and highly specific screening of HER2 overexpressed breast cancer. An antibody against HER2 protein receptor, EP1045Y, was conjugated with NIR emitting CdSeTe/CdS/ZnS QDs via polyhistidine-driven self-assembly approach. The further adsorption of black hole quencher 3 on antibody enabled a “turn on” fluorescence response of the fluorescence tracer to HER2 protein receptor. Aside from the capability of differentiating the HER2 overexpressed MCF-7 cells from its counterparts, the fluorescence tracer can also accurately and rapidly identify the HER2 overexpressed breast tumor subtype in two tumors-bearing mouse model, providing a platform for the investigation of advanced pathways to distinguish the different breast cancer subtypes.